Author
Listed:
- Kathryn J Swoboda
- Charles B Scott
- Sandra P Reyna
- Thomas W Prior
- Bernard LaSalle
- Susan L Sorenson
- Janine Wood
- Gyula Acsadi
- Thomas O Crawford
- John T Kissel
- Kristin J Krosschell
- Guy D'Anjou
- Mark B Bromberg
- Mary K Schroth
- Gary M Chan
- Bakri Elsheikh
- Louise R Simard
Abstract
: Preliminary in vitro and in vivo studies with valproic acid (VPA) in cell lines and patients with spinal muscular atrophy (SMA) demonstrate increased expression of SMN, supporting the possibility of therapeutic benefit. We performed an open label trial of VPA in 42 subjects with SMA to assess safety and explore potential outcome measures to help guide design of future controlled clinical trials. Subjects included 2 SMA type I ages 2–3 years, 29 SMA type II ages 2–14 years and 11 type III ages 2–31 years, recruited from a natural history study. VPA was well-tolerated and without evident hepatotoxicity. Carnitine depletion was frequent and temporally associated with increased weakness in two subjects. Exploratory outcome measures included assessment of gross motor function via the modified Hammersmith Functional Motor Scale (MHFMS), electrophysiologic measures of innervation including maximum ulnar compound muscle action potential (CMAP) amplitudes and motor unit number estimation (MUNE), body composition and bone density via dual-energy X-ray absorptiometry (DEXA), and quantitative blood SMN mRNA levels. Clear decline in motor function occurred in several subjects in association with weight gain; mean fat mass increased without a corresponding increase in lean mass. We observed an increased mean score on the MHFMS scale in 27 subjects with SMA type II (p≤0.001); however, significant improvement was almost entirely restricted to participants
Suggested Citation
Kathryn J Swoboda & Charles B Scott & Sandra P Reyna & Thomas W Prior & Bernard LaSalle & Susan L Sorenson & Janine Wood & Gyula Acsadi & Thomas O Crawford & John T Kissel & Kristin J Krosschell & Guy, 2009.
"Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy,"
PLOS ONE, Public Library of Science, vol. 4(5), pages 1-9, May.
Handle:
RePEc:plo:pone00:0005268
DOI: 10.1371/journal.pone.0005268
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0005268. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.